Zobrazeno 1 - 10
of 341
pro vyhledávání: ''
Autor:
Julio C. Chavez, James Drew, John P. Leonard, Erin Mulvey, Sonali M. Smith, Leandro Cerchietti, Nancy L. Bartlett, John L. Reagan, Jeffrey A. Jones, Ann S. LaCasce, Peter Martin, Maria Victoria Revuelta, Chengqing Wu
Publikováno v:
Blood. 139:1147-1159
Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large B-cell lymphoma (DLBCL), and aberrant DNA methylation may contribute to chemoresistance. Promising early-phase results were reported with rituximab, cyclophosphamid
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2
Autor:
Brigitte Senechal, Mark B. Geyer, Marco L. Davila, Kevin J. Curran, Mithat Gonen, Mikhail Roshal, Isabelle Riviere, Michel Sadelain, Peter Maslak, Jessica Flynn, Kitsada Wudhikarn, Claudia Diamonte, Renier J. Brentjens, Jae H. Park, Xiuyan Wang, Elizabeth Halton
Publikováno v:
Blood
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult
Autor:
Jaclyn Garza Grenier, R. Coleman Lindsley, Corey Cutler, Wael Saber, Mikko Myllymäki, Zhen-Huan Hu, Donna Neuberg, Christopher R. Reilly, Stephen R. Spellman, Esther H. Orr, Immaculata De Vivo, Joseph H. Antin, Tao Wang, Christopher J. Gibson, Maxine M. Chen, David P. Steensma, Robert A. Redd, Suneet Agarwal
Publikováno v:
Blood
Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for patients with myelodysplastic syndrome (MDS), but long-term survival is limited by the risk of transplant-related complications. Short telomere length,
Autor:
Kerry J. Savage, David Scott, Derrick G. Lee, Andrea Lo, Ciara L. Freeman, Anna Hayden, Francois Benard, Joseph M. Connors, Laurie H. Sehn, Diego Villa, Tom Pickles, Alina S. Gerrie, Pedro Farinha, Brian Skinnider, Donald A. Wilson, Petter Tonseth, Graham W. Slack, Paul R. Yenson
Publikováno v:
Blood. 136:2803-2811
Cure rates for primary mediastinal large B-cell lymphoma (PMBCL) have improved with the integration of rituximab. However, the type of primary therapy and role of radiotherapy (RT) remains ill-defined. Herein, we evaluated the outcome of PMBCL primar
Autor:
Hao-Wei Wang, Pamela L. Wolters, Kathryn Lurain, Stefania Pittaluga, Thomas S. Uldrick, Constance M. Yuan, Jomy M. George, Elaine S. Jaffe, Anaida Widell, Ramya Ramaswami, Priscila H. Goncalves, Richard F. Little, Mary Anne Tamula, Robert Yarchoan, Staci Martin, Mark N. Polizzotto, Seth M. Steinberg
Publikováno v:
Blood
Autor:
Jack Bartram, Michelle Cummins, Sara Ghorashian, Vasudha Nandagudi Rao, Brenda Gibson, Vesna Pavasovic, P Ancliff, Anupama Rao, Katherine Clesham, Beki James, Andrea Malone, Ajay Vora, Sujith Samarasinghe, Katharine Patrick, David O'Connor, Denise Bonney
Publikováno v:
Blood. 135:1501-1504
Autor:
Cheng Cheng, Raul C. Ribeiro, Francisco Pedrosa, Marcia Pedrosa, Ester Vinhas, Elaine Coustan-Smith, Alessandra Maria de Luna Ramos, Arli Pedrosa, Norma Lucena-Silva, Gaston K. Rivera, Yinmei Zhou, Dario Campana, Mecneide Mendes Lins
Publikováno v:
Blood. 135:1458-1466
Treatment-related mortality is common among children with acute lymphoblastic leukemia (ALL) treated in poor-resource settings. We applied a simplified flow cytometric assay to identify patients with precursor B-cell ALL (B-ALL) at very low risk (VLR
Autor:
Fernando A. Bozza, Lívia Teixeira, Ester A. Barreto, Eugenio D. Hottz, Cassia Righy, Camila R. R. Pão, Pedro Kurtz, Lohanna Palhinha, Sérgio Franco, Thiago Moreno L. Souza, Patrícia T. Bozza, Isaclaudia G. de Azevedo-Quintanilha
Publikováno v:
Blood
There is a Blood Commentary on this article in this issue.
Key Points Increased platelet activation and platelet-monocyte aggregate formation associate with poor outcome in severe COVID-19 patients. Platelets from severe COVID-19 patients induce
Key Points Increased platelet activation and platelet-monocyte aggregate formation associate with poor outcome in severe COVID-19 patients. Platelets from severe COVID-19 patients induce
Autor:
Darren Foard, Sajitha Sachchithanantham, Cristina Quarta, Shameem Mahmood, Faye Sharpley, Philip N. Hawkins, Oliver C Cohen, Richa Manwani, Helen J. Lachmann, Carol J. Whelan, Marianna Fontana, Julian D. Gillmore, Ashutosh D. Wechalekar
Publikováno v:
Blood. 134:2271-2280
Bortezomib is a standard therapy in light-chain amyloidosis (AL), but little is known about response duration. A difference in involved amyloidogenic and uninvolved serum-free light chains (dFLC)10 mg/L (low dFLC response) predicts survival in AL pat